

Accepted Manuscript

Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in copd patients

Marietta Rottenkolber , Dominik Rottenkolber , Dr. Rainald Fischer , PD Dr. Luisa Ibáñez , MD PhD, Dr. Joan Fortuny , Elena Ballarin , Monica Sabaté , Pili Ferrer , Petra Thürmann , Prof. Dr. Joerg Hasford , Prof. Dr. Sven Schmiedl , Dr.

PII: S0954-6111(14)00201-7

DOI: [10.1016/j.rmed.2014.05.014](https://doi.org/10.1016/j.rmed.2014.05.014)

Reference: YRMED 4519

To appear in: *Respiratory Medicine*

Received Date: 18 February 2014

Revised Date: 22 May 2014

Accepted Date: 27 May 2014

Please cite this article as: Rottenkolber M, Rottenkolber D, Fischer R, Ibáñez L, Fortuny J, Ballarin E, Sabaté M, Ferrer P, Thürmann P, Hasford J, Schmiedl S, Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in copd patients, *Respiratory Medicine* (2014), doi: 10.1016/j.rmed.2014.05.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



INHALED BETA-2-AGONISTS/MUSCARINIC ANTAGONISTS and ACUTE MYOCARDIAL INFARCTION IN COPD PATIENTS

Authors: Marietta Rottenkolber¹, Dominik Rottenkolber^{2,3}, Rainald Fischer⁴, Luisa Ibáñez^{5,6}, Joan Fortuny⁷, Elena Ballarín^{5,6}, Monica Sabaté^{5,6}, Pili Ferrer⁵, Petra Thürmann^{8,9}, Joerg Hasford¹, Sven Schmiedl^{8,9}

¹Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Munich, Germany ²Institute of Health Economics and Management, Ludwig-Maximilians-Universität München, Munich, Germany ³Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany ⁴Medizinische Klinik und Poliklinik V, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany ⁵Fundació Institut Català de Farmacologia Servei de Farmacologia, Hospital Universitari Vall d'Hebron ⁶Departament de Farmacologia, Terapèuticai Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain ⁷Novartis Farmaceutica S.A., Barcelona, Spain ⁸Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany ⁹Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany

Corresponding author:

Dipl.-Stat. Marietta Rottenkolber, Institute for Medical Information Sciences, Biometry, and Epidemiology Ludwig-Maximilians Universität München, Marchioninstr. 15, D-81377 Munich, Germany
Tel.: +49 89 2180 72406, Fax: +49 89 2180 72404, E-mail: rottenk@ibe.med.uni-muenchen.de

Authors:

Dr. Dominik Rottenkolber
Institute of Health Economics and Health Care Management and Munich Centre of Health Sciences,
Ludwig-Maximilians-Universität München / Helmholtz Zentrum München - German Research Centre for
Environmental Health
Ludwigstr. 28
D-80539 München
Germany

PD Dr. Rainald Fischer
Medizinische Klinik und Poliklinik V, University Hospital, Ludwig-Maximilians-Universität
Ziemssenstr. 1
D-80336 München
Germany

Dr. Luisa Ibáñez, MD PhD
Fundació Institut Català de Farmacologia / Departament de Farmacologia, Terapèuticai Toxicologia, Universitat
Autònoma de Barcelona
Hospital Universitari Vall d'Hebron
Pg Vall d'Hebron 119-129
E-08029 Barcelona
Spain

Joan Fortuny
Novartis Farmaceutica S.A.
Apartado 708
E-08080 Barcelona

Download English Version:

<https://daneshyari.com/en/article/6241950>

Download Persian Version:

<https://daneshyari.com/article/6241950>

[Daneshyari.com](https://daneshyari.com)